This clinical trial is focused on studying a type of cancer called relapsed/refractory B-cell non-Hodgkin’s lymphoma. This is a condition where a type of white blood cell, known as B-cells, becomes cancerous and either returns after treatment or does not respond to treatment. The study is testing a new treatment approach using two medications: Glofitamab and Obinutuzumab. Glofitamab is a special type of protein designed to help the immune system target and destroy cancer cells. Obinutuzumab is another protein that helps the immune system attack cancer cells and is given as a pre-treatment to prepare the body for Glofitamab.
The purpose of the study is to find the best dose of Glofitamab when used alone and in combination with Obinutuzumab, and to understand how safe and effective these treatments are for patients with this type of lymphoma. Participants in the study will receive these medications through an infusion, which means the medicine is given directly into the bloodstream through a vein. The study will monitor how the body responds to the treatment, including any side effects and how well the cancer responds.
Throughout the study, doctors will carefully observe the participants to ensure their safety and to gather information on how the treatment affects the cancer. The study aims to provide valuable insights into the potential benefits and risks of using Glofitamab and Obinutuzumab for treating relapsed/refractory B-cell non-Hodgkin’s lymphoma, which could lead to new treatment options for patients in the future.
Belgium 
Czechia 
Denmark 
Finland 
France 
Italy 
Poland 
Spain 
